Presentation: Q1 2024 MedLife Group Financial Results

hyper clinics | hospitals | maternities |

laboratories | excellence centers | pharmacies

Q1 2024 Results

Presentation

10 May 2024

www.medlife.ro/www.medlifeinternational.com

LegalDisclaimer

This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA's securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA's securities.

Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any investor.

All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate.

Med Life SA has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein.

This report may contain forward-looking statements. These statements reflect Med Life SA's current knowledge and its expectations and projections/forecasts about future

events and may be identified by the context of such statements or words such as "forecast", "forecasted", "anticipate," "believe", "estimate", "expect", "intend", "plan", "project", "target", "may", "will", "would", "could" or "should" or similar terminology.

These financial projections/forecasts are in compliance with the Policy on Forecast of MedLife Group published on its website: https://www.medlifeinternational.com/public_files/documente_bursa/policy_of_forecast.pdf

These financial projections/forecasts are preliminary and subject to change; Med Life SA undertakes no obligation to update or revise these forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. Inevitably, some assumptions may not materialize, and unanticipated events and circumstances may affect the ultimate financial results. Projections are inherently subject to substantial and numerous uncertainties and to a wide variety of significant business, economic and competitive risks.

These projections should not be considered a comprehensive representation of Med Life SA's cash generation performance.

Therefore, the final results achieved may vary significantly from the forecasts, and the variations may be material.

2

AGENDA

1

2

3

3mo 2024 Highlights

Financial overview

Q&A Session

• Key messages
• Outlook
• Consolidated Statement of Profit and Loss
• Consolidated Statement of Financial Position
• Consolidated Statement of Cash Flow

3

3mo 2024 Highlights

• Key messages
• Outlook

1

hyper clinics | hospitals | maternities |

laboratories | excellence centers | pharmacies

Keymessages

• Consistent evolution of the financial and operational performance of the Group;
• Consolidated pro-formaTurnover of RON 647 million, up by 22% compared to same period last year;
• Strong organic growth of 15% in revenues, with sustained demand for medical services, creating growth premises for the rest of the year;
• Robust increase in EBITDA margins YoY, on the back of integration of the acquired companies in the Group and sustained organic development investments which started to contribute to overall profitability;
• 33% increase in pro-formaEBITDA, to RON 99 million;
• 65% increase in pro-formanet result, to RON 14 million;
• Completed the acquisition of Personal Genetics (genetics laboratory), thus becoming the provider with the greatest expertise in the area of genetics and molecular biology in Romania.

	1. 3mo 2024 Highlights		2. Financial Overview		3. Q&A session	5

hyper clinics | hospitals | maternities |

laboratories | excellence centers | pharmacies

Outlook

Focus on:

• optimizing the operational flows and procedures within the group, in order to further leverage the economies of scale and cumulated expertise of each unit;
• consolidating profitability margins y.o.y. after important investments carried out in the past years, both in terms of M&A and organic projects;
• gradual reduction of net debt to EBITDA levels.

Strategic priorities:

• continued development of the MedLife Medical Park project;
• finalization of the Medici`s Hospital in Timisoara & MedLife Hospital in Craiova;
• CAPEX estimated to EUR 25m for 2024, including maintenance CAPEX.

In terms of acquisitions, we will maintain the acquisitive profile that brought this growth, as well as organic investments, maintaining, however, as in the first quarter, a special attention on the improvement of margins compared to the previous year and reducing the net debt/EBITDA ratio.

	1. 3mo 2024 Highlights		2. Financial Overview		3. Q&A session	6

Financialoverview

• Consolidated Statement of Profit and Loss
• Consolidated Statement of Financial Position
• Consolidated Statement of Cash Flow

2

hyper clinics | hospitals | maternities |

laboratories | excellence centers | pharmacies

ConsolidatedStatementofProfitandLoss

• Consolidated pro-forma Turnover of RON 647m, up by 22% YoY, with a strong evolution in almost all business lines;

• Pro-forma EBITDA increased by 33% to RON 99m, reaching a margin of 16.1% (15.2% IFRS basis, increase from 14.1% in the same period last year);

• Net Result increased by 65% to RON 13.8m, reaching a margin of 2.3% (2.0% on IFRS basis, increase from 1.6% in the same period last year), still affected by high yields environment which resulted in higher financing cost.

	1. 3mo 2024 Highlights		2. Financial Overview		3. Q&A session	8

hyper clinics | hospitals | maternities |

laboratories | excellence centers | pharmacies

ConsolidatedStatementofProfitandLoss - Pro-formaRevenues

From IFRS Revenues to Pro-forma Revenues:

• No normalization adjustments from acquisitions, with Personal Genetics SPA completed in April (Sales of RON 14m in 2023);

• RON 32 million reclass related to the National Program for chemotherapy drugs.

	1. 3mo 2024 Highlights		2. Financial Overview		3. Q&A session	9

hyper clinics | hospitals | maternities |

laboratories | excellence centers | pharmacies

ConsolidatedStatementofProfitandLoss - Pro-formaEBITDA

From IFRS EBITDA to Pro-forma EBITDA:

• No impact in EBITDA pro-forma coming from acquisitions;

• ~ RON 1 million one-off expenses adjusted in pro-forma EBITDA.

	1. 3mo 2024 Highlights		2. Financial Overview		3. Q&A session	10